drugset / Trial / NCT03827876

Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

NCT03827876

NaSingle-groupOpen-labelTreatment

Summary

4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks

Timeline

Start
2019-01-16
Primary completion
2019-09-15
Completion
2019-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcipotriol Small molecule 0.005 % Topical
Subject betamethasone dipropionate Small molecule 0.064 % Topical

Indications